



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61F 2/02, 6/06, 9/02, A61K 9/20, 9/48, C07D 211/08</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/36554</b> <b>(43) International Publication Date:</b> 9 October 1997 (09.10.97)
<b>(21) International Application Number:</b> PCT/US97/02865 <b>(22) International Filing Date:</b> 25 February 1997 (25.02.97)  <b>(30) Priority Data:</b> 08/625,718                      29 March 1996 (29.03.96)                      US  <b>(71) Applicant:</b> VIROPHARMA INCORPORATED [US/US]; 76 Great Valley Parkway, Malvern, PA 19355 (US).  <b>(72) Inventors:</b> DIANA, Guy, D.; 1566 Glenmar Drive, Pottstown, PA 19465 (US). BAILEY, Thomas, R.; 217 Amanda Lane, Phoenixville, PA 19460 (US). NITZ, Theodore, J.; 473 Kulp Road, Pottstown, PA 19465 (US).  <b>(74) Agents:</b> HAGAN, Patrick, J. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103-2307 (US).		<b>(81) Designated States:</b> CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF HEPATITIS C  <b>(57) Abstract</b>  Derivatives of piperidine are useful in prophylaxis and treatment of hepatitis C virus infections.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

"PIPERIDINE  
DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN  
THE TREATMENT OF HEPATITIS C"

FIELD OF THE INVENTION

The present invention relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel piperidine  
5 derivatives, pharmaceutical compositions containing such compounds and methods of using the compounds in treating HCV and other viral diseases.

BACKGROUND OF THE INVENTION

10 HCV, which is found in all parts of the world, has been characterized as single-stranded RNA virus of about 9.5 kilobases in length. Choo et al., Science, 244: 395-62 (1989).

15 Surgery patients and others requiring blood transfusions, and especially those having suppressed immune systems, resulting, for example, from drugs administered in connection with organ transplantation, are at risk of developing HCV infection, which is the primary cause of transfusion-associated hepatitis in  
20 the world today. It has been estimated that posttransfusion hepatitis C may be responsible for up to 3,000 annual cases of chronic active hepatitis or cirrhosis of the liver in the U.S. alone. Hemodialysis patients, as well as intravenous drug  
25 abusers are other groups which are at risk for acquiring HCV infection.

The mechanism by which HCV replicates has not been thoroughly elucidated, thus hindering research aimed at developing an effective vaccine.  
30 Immune globulin has been reported for prophylaxis of transfusion-associated viral hepatitis. However, the


Centers for Disease Control do not presently recommend immune globulin for this purpose.

Various clinical studies have been conducted with the goal of identifying pharmaceutical agents capable of effectively treating HCV infection in patients afflicted with chronic hepatitis C. These studies have involved the use of dideoxynucleoside analogues and interferon-alpha, alone and in combination therapy with other anti-viral substances. Such studies have shown, however, that substantial numbers of the participants do not respond to this therapy, and of those that do respond favorably, a large proportion were found to relapse after termination of treatment.

Thus, a need exists for new anti-viral agents and treatments for HCV infection that overcome the limitations of existing pharmaceutical therapies. Insofar as is known, piperidine derivatives of the type described herein have not been previously reported as being useful for the treatment of HCV.

#### SUMMARY OF THE INVENTION

In accordance with one aspect, the present invention provides compounds, including isomers, having the following structure:




in which R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are the same or different and represent substituents selected from the group

consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ ;

5 W and X represent the same or different linking moieties selected from the group consisting of alkylene ( $C_1-C_5$ ) and carbonyl ( $-(C=O)-$ ); Y and Z represent the same or different substituents selected from the group consisting of


10




in which  $R_5$  represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ) and acyl, and each  $R_6$  is the same or different and represents a  
15 substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ , and  $m$  is 1-4, and  
20 in which  $R_7$  represents a substituent selected from the group consisting of hydrogen, alkyl and acyl, and  $n$  is from 3 to 5, and the isomers and pharmaceutically acceptable salts of those compounds.

In accordance with another aspect, the  
25 present invention provides a class of intermediates which are useful in preparing compounds of formula I, above. The intermediates of the invention have the structure:

30



in which R<sub>8</sub> represents a carbalkoxy (C<sub>1</sub>-C<sub>6</sub>) substituent or



10

According to still another aspect, the present invention provides pharmaceutical compositions comprising one or more of the above-described piperidine derivatives in combination with a pharmaceutically acceptable carrier medium.

In accordance with yet another aspect, the present invention provides a method for treating viral hepatitis C infections in mammalian hosts by administering an effective amount of the compounds of the invention to a patient susceptible to hepatitis C infection or suffering from such an infection.

#### DETAILED DESCRIPTION OF THE INVENTION


The compounds of the invention can be conveniently prepared from known starting materials according to reactions described in the examples.

In vitro studies demonstrating the usefulness of the compounds of the invention as anti-viral agents have been performed. Anti-viral activity was measured on the basis of inhibition of helicase activity. The biological studies of the anti-viral activity of the compounds of the invention are


described below.

The term "alkyl" as used herein refers to aliphatic hydrocarbon radicals of one to six carbon atoms in length. Similarly, the term "alkyl", or variations thereof, used in combination form to name substituents such as carbalkoxy, alkoxy, alkylthio, alkylamino, alkylsulfinyl or alkylsulfonyl also refers to aliphatic hydrocarbon radicals of one to six carbon atoms in length, and preferably of one to four carbon atoms in length.

Among the particularly preferred embodiments of the invention are compounds, including isomeric forms, having the formula:




in which  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same or different and represent substituents selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ ; Y and Z represent the same or different substituent selected from the group consisting of




in which  $R_5$  represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ) and acyl, and each  $R_6$  is the same or different and represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ , and  $m$  is 1-4, and in which  $R_7$  represents a substituent selected from the group consisting of hydrogen, alkyl and acyl, and  $n$  is from 3 to 5, and the pharmaceutically acceptable salts of such compounds.

Also preferred are compounds, including isomeric forms, having the formula:



in which  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same or different and represent substituents selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ ;  $Y$  and  $Z$  represent the same or different substituent selected from the group consisting of





in which R<sub>5</sub> represents a substituent selected from the group consisting of hydrogen, alkyl (C<sub>1</sub>-C<sub>6</sub>) and acyl, and each R<sub>6</sub> is the same or different and represents a substituent selected from the group consisting of hydrogen, alkyl (C<sub>1</sub>-C<sub>6</sub>), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and NO<sub>2</sub>, and m is 1-4, and wherein R<sub>7</sub> represents a substituent selected from the group consisting of hydrogen, alkyl and acyl, and n is from 3 to 5, and the pharmaceutically acceptable salts of this compound.

Isomers of the above-described compounds such as those in which the piperidine moieties are in the meta- or para-position relative to one another on the central phenylene nucleus may be used in practicing the invention.

As previously noted, the compounds of formula I, above, including their pharmaceutically acceptable salts, exhibit antiviral activity against hepatitis C virus.

The compounds of the invention can form salts with inorganic and organic acids, including, for example, acids such as hydrochloric acid, hydrobromic acid and methanesulfonic acid.

The pharmaceutically acceptable salts of the compounds of formulas I and II are prepared following procedures which are familiar to those skilled in the art.

The antiviral pharmaceutical compositions of

the present invention comprise one or more of the compounds of formula I, above, as the active ingredient in combination with a pharmaceutically acceptable carrier medium or auxiliary agent.

5           The composition may be prepared in various forms for administration, including tablets, caplets, pills or dragees, or can be filled in suitable containers, such as capsules, or, in the case of suspensions, filled into bottles. As used herein,  
10   "pharmaceutically acceptable carrier medium" includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and  
15   the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Fifteenth Edition, E.W. Martin (Mack Publishing Co., Easton, PA, 1975) discloses various carriers used in formulating pharmaceutical compositions and known  
20   techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the anti-viral compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a  
25   deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention. In the pharmaceutical compositions of the invention, the active agent may be present in an amount of at least  
30   0.5% and not more than 90% by weight based on the total weight of the composition, including carrier medium and/or auxiliary agent(s). Preferably, the proportion of active agent varies between 5%-50% by weight of the composition. Pharmaceutical organic or  
35   inorganic solid or liquid carrier media suitable for enteral or parenteral administration can be used to make up the composition. Gelatine, lactose, starch,

magnesium, stearate, talc, vegetable and animal fats and oils, gum, polyalkylene glycol, or other known excipients or diluents for medicaments may all be suitable as carrier media.

5           The compounds of the invention may be administered using any amount and any route of administration effective for attenuating infectivity of the hepatitis C virus. Thus, the expression "therapeutically effective amount", as used herein,  
10           refers to a nontoxic but sufficient amount of the antiviral agent to provide the desired treatment of viral infection. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the  
15           severity of the infection, the particular antiviral agent and its mode of administration, and the like. The anti-hepatitis C compounds are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit  
20           form as used herein refers to a physically discrete unit of anti-viral agent appropriate for the patient to be treated. Each dosage should contain the quantity of active material calculated to produce the desired therapeutic effect either as such, or in  
25           association with the selected pharmaceutical carrier medium. Typically, the anti-viral compounds of the invention will be administered in dosage units containing from about 1 mg to about 500 mg of the anti-viral agent by weight of the composition with a  
30           range of about 1 mg to about 50 mg being preferred.

          The compounds of the invention may be administered orally, parenterally, such as by intramuscular injection, intraperitoneal injection, intravenous infusion or the like, depending on the  
35           severity of the infection being treated. The compounds of the invention may be administered orally or parenterally at dosage levels of about 0.1 to about

50 and preferably from about 1 to about 10 mg/kg, of patient body weight per day, one or more times a day, to obtain the desired therapeutic effect.

Although the piperidine derivatives can be administered to any patient which is susceptible to hepatitis C infection, the compounds are intended for the treatment of mammalian hosts, and especially humans.

The compounds of the invention will typically be administered from one to four times a day so as to deliver the above-mentioned daily dosage. However, the exact regimen for administration of the compounds and compositions described herein will necessarily be dependent on the needs of the individual patient being treated, the type of treatment administered and the judgment of the attending physician.

In view of the inhibitory effect on helicase enzyme activity produced by the compounds of the invention, it is anticipated that these compounds will be useful not only for therapeutic treatment of infection, but for hepatitis C viral prophylaxis, as well. The above-noted dosages will be essentially the same whether for treatment or prophylaxis of hepatitis C infection.

The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and not to limit the invention.

Examples 1 to 5 illustrate the chemical synthesis of the compounds of the invention.

#### EXAMPLE 1

Preparation of 1,1'-[1,4-phenylene bis(methylene)]bis(4,4'-carboxyethoxy)piperidine  
A suspension of 5.0 g (18.0 mmol) of 4-

-11-

dibromoxylene, 6.0 g (37.8 mmol) of ethyl  
isonipecotatate, and 6.5 g (57.0 mmol) of milled  
potassium carbonate in 100 ml of ethanol was refluxed  
under nitrogen for 16 hours. The suspension was  
5 cooled to room temperature, and then filtered. The  
filtrate was concentrated in vacuo to provide 10 g of  
the crude product as a white solid. Recrystallization  
from ethyl acetate/hexanes yielded 7.0 g (89% yield)  
of the product as a white solid with a melting point  
10 of 72-74°.

#### EXAMPLE 2

Preparation of 1,1'-[1,4-  
phenylenebis(methylene)]bis(4,4'-(N,N'-trans-2-  
15 aminocyclohexyl)carboxamido)piperidine

A suspension of 1.12 g (2.7 mmol) of 1,1'-  
[1,4-phenylene bis(methylene)]bis(4,4'-  
carboxyethoxypiperidine in 20 ml of trans-1,2-  
diaminocyclohexane was refluxed under nitrogen for 22  
20 hours. Upon cooling, a white precipitate was  
recovered by filtration, and washed with ether  
followed by water. After drying under vacuum at 50°C  
for 16 hours, there was recovered 0.57 g (38% yield)  
of the product as a fine, white solid with a melting  
25 point greater than 250°C.

#### EXAMPLE 3

Preparation of 1,1'-[1,4-  
phenylenebis(methylene)]bis(4,4'-trans-(4,5,6,7,8,9-  
30 hexahydro)benzimidazolyl)piperidine

A mixture of 0.50 g of 1,1'-[1,4-  
phenylenebis(methylene)]bis(4,4'-(N,N'-trans-2-  
aminocyclohexyl)carboxamido)piperidine and 1.2 g of  
phosphorous oxybromide was heated at 150°C for 30  
35 minutes. Upon cooling to room temperature, the light  
orange solid was dissolved in ice water, and the  
aqueous solution basified to pH 9 with 10% NaOH

-12-

solution. The tan solid was recovered by filtration yielding 53 mg (11% yield) of the crude product after drying in vacuo. The crude product was dissolved into 25 ml of ethanol, and the solution treated with 0.5 ml (excess) 1.0 M ethereal HCl. The precipitate was recovered by filtration, and dried in vacuo affording 51 mg of tetrahydrochloride salt as a tan powder with a melting point greater than 250°C.

10

**EXAMPLE 4****Preparation of 1,1'-[1,4-phenylenebis(methylene)]bis(4,4'-benzimidazolyl) piperidine**

A suspension of 1.00 g (2.4 mmol) of 1,1'-[1,4-phenylene bis(methylene)]bis(4,4'-carboxyethoxypiperidine and 0.52 g (4.8 mmol) of o-phenylenediamine was refluxed in 40 ml of 6N HCl for 5 days. Upon cooling, the green homogeneous solution was basified to pH 8 with solid NaOH and the precipitate recovered by filtration. The pink solid was washed with water and dried in vacuo for 12 hours, yielding 0.477 g of the crude product as a pink solid. The crude product was suspended in 3 mL of phosphorous oxychloride and heated in a sealed tube at 150°C for 4 hours. Upon cooling, the slurry was poured over ice and the green solution filtered through Solka Floc. The filtrate was basified with solid NaOH and the tan precipitate was collected by filtration. The filter cake was washed with water and dried in vacuo at 80°C for 14 hours to provide 0.269 g (22% yield) of the product as a pink/tan powder with a melting point greater than 250°C.

35

**EXAMPLE 5****Preparation of 1,1'-[1,4-phenylenebis(carbonyl)]bis(4,4'-benzimidazolyl) piperidine**

A suspension of 1.00 g (5.0 mmol) 4-(benzimidazole) piperidine, 0.508 (2.5 mmol) of terephthaloyl chloride and 1.45 mL (11.2 mmol) of diisopropylethylamine in 15 mL of dry dimethylformamide was allowed to stir at room temperature under nitrogen for 16 hours. The mixture was diluted with 20 mL of water and the precipitate was collected by filtration and washed with water. Drying in vacuo at 40°C provided 0.869 g (46% yield) of the product as a tan/pink solid with a melting point greater than 250°C.

Example 6 illustrates the efficacy of compounds of the invention in inhibiting the viral helicase activity.

#### EXAMPLE 6

##### Assay for Helicase Inhibition

The helicase inhibition assay was performed according to methodology of the type described, for example, in: Lain et al., Nucleic Acids Res. 18:7003-7006 (1991); Warrenner et al., J. Virol. 69:1720-1726 (1995); Kim et al., Biochem. Biophys. Res. Comm. 214:160-166 (1995). The value given in Table 1 represent the average of three test results in which the concentrations of anti-viral compound required to achieve a 50% inhibition of helicase activity ( $IC_{50}$ ) were measured.

30

TABLE 1

Example Number	$IC_{50}$ ( $\mu M$ )
3	7

The relatively low concentration of the anti-viral compound of the invention required to achieve 50% inhibition of the viral helicase activity tends to show that the compounds of the invention are


effective at interfering with propagation of HCV.

Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be  
5 apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which  
10 is delineated by the appended claims.




## WHAT IS CLAIMED IS:

1. A compound having the formula:



- 15
- 20
- 25
- wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same or different and represent substituents selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ ; W and X represent the same or different linking moieties selected from the group consisting of alkylene ( $C_1-C_5$ ) and carbonyl ( $-(C=O)-$ ); Y and Z represent the same or different substituents selected from the group consisting of




- 30
- wherein  $R_5$  represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ) and acyl, and each  $R_6$  is the same or different and represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy,

carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $\text{NO}_2$ , and  $m$  is 1-4, and wherein  $R_7$  represents a substituent selected from the group consisting of hydrogen, alkyl and acyl, and  $n$  is from 3 to 5; and the isomers and pharmaceutically acceptable salts of said compounds.

2. A compound having the formula


10

15



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same or different and represent substituents selected from the group consisting of hydrogen, alkyl ( $\text{C}_1\text{-C}_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $\text{NO}_2$ ;  $Y$  and  $Z$  represent the same or different substituent selected from the group consisting of

25



wherein  $R_5$  represents a substituent selected from the group consisting of hydrogen, alkyl ( $\text{C}_1\text{-C}_6$ ) and acyl,


30

and each  $R_6$  is the same or different and represents a substituent selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen, hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acetamido, sulfonamido, alkylamino, dialkylamino and  $NO_2$ , and  $m$  is 1-4, and wherein  $R_7$  represents a substituent selected from the group consisting of hydrogen, alkyl and acyl, and  $n$  is from 3 to 5; and the isomers and pharmaceutically acceptable salts of said compound.

3. The compound 1,1'-[1,4-phenylenebis(methylene)]bis(4,4'-trans-(4,5,6,7,8,9-hexahydro)benzimidazolyl)piperidine and the pharmaceutically acceptable salts of said compound, as claimed in claim 2.


4. The compound 1,1'-[1,4-phenylenebis(methylene)]bis(4,4'-benzimidazolyl)piperidine and the pharmaceutically acceptable salts of said compound, as claimed in claim 2.

5. A compound having the formula



wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same or different and represent substituents selected from the group consisting of hydrogen, alkyl ( $C_1-C_6$ ), halogen,


hydroxy, alkoxy, carboxy, carbalkoxy, alkylthio,  
alkylsulfinyl, alkylsulfonyl, amino, acetamido,  
sulfonamido, alkylamino, dialkylamino and  $\text{NO}_2$ ; Y and Z  
represent the same or different substituent selected  
5 from the group consisting of



wherein  $R_5$  represents a substituent selected from the  
group consisting of hydrogen, alkyl ( $\text{C}_1\text{-C}_6$ ) and acyl,  
10 and each  $R_6$  is the same or different and represents a  
substituent selected from the group consisting of  
hydrogen, alkyl ( $\text{C}_1\text{-C}_6$ ), halogen, hydroxy, alkoxy,  
carboxy, carbalkoxy, alkylthio, alkylsulfinyl,  
15 alkylsulfonyl, amino, acetamido, sulfonamido,  
alkylamino, dialkylamino and  $\text{NO}_2$ , and m is 1-4, and  
wherein  $R_7$  represents a substituent selected from the  
group consisting of hydrogen, alkyl and acyl, and n is  
from 3 to 5; and the isomers and pharmaceutically  
20 acceptable salts of said compound.

6. The compound 1,1'-[1,4-  
phenylenebis(carbonyl)]bis(4,4'-  
benzimidazolyl)piperidine and the pharmaceutically  
25 acceptable salts of said compound, as claimed in claim  
5.

7. A compound having the formula




5

wherein  $R_8$  represents a carbalkoxy ( $C_1-C_6$ ) substituent.

8. A compound having the formula


10



15

wherein  $R_8$  represents

20



25

9. A pharmaceutical composition for treating hepatitis C virus infection, said composition comprising a compound as claimed in claim 1 in an amount effective to attenuate infectivity of said virus, and a pharmaceutically acceptable carrier medium.

30

10. A composition as claimed in claim 9 in the form of a solid with a pharmaceutically acceptable excipient.

35

11. A composition as claimed in claim 9 in the form

of a liquid with a pharmaceutically acceptable diluent.

5 12. A composition as claimed in claim 9 comprising from about 5 to about 50 mg of said compound by weight of said composition.

10 13. A method of treatment of hepatitis C virus infection in a patient in need of said treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

15 14. A method as claimed in claim 13, wherein said compound is administered in unit dosage form containing about 5 to about 50 mg of said compound per kilogram of patient body weight per day.

20 15. A method as claimed in claim 14, wherein said unit dosage includes a pharmaceutically acceptable carrier medium.

25 16. A method as claimed in claim 13, wherein said composition is administered parenterally.

17. A method as claimed in claim 13, wherein said composition is administered orally.

30 18. A method of preventing hepatitis C virus infection in a host susceptible to said infection, said method comprising administering to said host a prophylactically effective amount of a compound of claim 1.

35 19. A method as claimed in claim 18, wherein said compound is administered in unit dosage form containing about 5 to about 50 mg of said compound per

kilogram of patient body weight per day.

20. A method as claimed in claim 19, wherein said  
unit dosage includes a pharmaceutically acceptable  
5 carrier medium.

21. A method as claimed in claim 18, wherein said  
composition is administered parenterally.

10 22. A method as claimed in claim 18, wherein said  
composition is administered orally.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/02865

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : A61F 2/02, 6/06, 9/02; A61K 9/20, 9/48; C07D 211/08 US CL : 424/423, 427, 430, 437, 439, 451, 464; 546/191 According to International Patent Classification (IPC) or to both national classification and IPC																				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/423, 427, 430, 437, 439, 451, 464; 546/191  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)																				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A	US 5,356,880 A (KURONO et al.) 18 October 1994, see entire document.	1-22																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"><tr><td colspan="2">* Special categories of cited documents:</td><td></td></tr><tr><td>*A*</td><td>document defining the general state of the art which is not considered to be of particular relevance</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*E*</td><td>earlier document published on or after the international filing date</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*L*</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*O*</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P*</td><td>document published prior to the international filing date but later than the priority date claimed</td><td>*A* document member of the same patent family</td></tr></table>			* Special categories of cited documents:			*A*	document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*E*	earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O*	document referring to an oral disclosure, use, exhibition or other means		*P*	document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family
* Special categories of cited documents:																				
*A*	document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
*E*	earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
*O*	document referring to an oral disclosure, use, exhibition or other means																			
*P*	document published prior to the international filing date but later than the priority date claimed	*A* document member of the same patent family																		
Date of the actual completion of the international search 11 APRIL 1997		Date of mailing of the international search report 05 JUN 1997																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer Carlos Azpuru <i>gab for</i> Telephone No. (703) 308-2351																		